Open access
Jul 2026
Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan.
Results support mRNA-1083 as a single-dose approach to seasonal vaccination against influenza and SARS-CoV-2 in adults ≥50 years and noninferiority of mRNA-1083 was demonstrated for comparator-matched influenza strains and SARS-CoV-2.
Lusine Kostanyan, Hiroyuki Fukase, Alexander Rumyantsev et al.
· Vaccine · 0 citations